Repository logo
Communities & Collections
All of DSpace
  • English
  • العربية
  • বাংলা
  • Català
  • Čeština
  • Deutsch
  • Ελληνικά
  • Español
  • Suomi
  • Français
  • Gàidhlig
  • हिंदी
  • Magyar
  • Italiano
  • Қазақ
  • Latviešu
  • Nederlands
  • Polski
  • Português
  • Português do Brasil
  • Srpski (lat)
  • Српски
  • Svenska
  • Türkçe
  • Yкраї́нська
  • Tiếng Việt
Log In
New user? Click here to register.Have you forgotten your password?
  1. Home
  2. Browse by Author

Browsing by Author "OJO, Oluwaferanmi Esther"

Filter results by typing the first few letters
Now showing 1 - 1 of 1
  • Results Per Page
  • Sort Options
  • No Thumbnail Available
    Item
    IN VIVO IN VITRO ANTI-PLASMODIAL ACTIVITY OF CHEMICALLY SYNTHESISED IMIDAZOLE COMPOUNDS
    (Covenant University, Ota, 2026-09) OJO, Oluwaferanmi Esther; Covenant University, Dissertation
    Malaria remains a leading cause of morbidity and mortality globally, with the continued emergence of Plasmodium falciparum resistance to artemisinin-based therapies rendering the identification of novel chemotherapeutic scaffolds an urgent priority. The imidazole family of compounds, with their adaptable framework and ability to engage parasite-specific targets such as falcipain-2 and hemozoin biosynthesis machinery, represent compelling synthetic leads. This study evaluates the in vitro anti-plasmodial activity and in vivo efficacy and safety profiles of two newly synthesised compounds: 4,5-diphenyl-2-(m-tolyl)-1H-imidazole (IM1) and 4,5-diphenyl-2- (m-tolyl)-1-tosyl-1H-imidazole (IM2). In vitro susceptibility was assessed using a schizont maturation inhibition assay against the chloroquine-sensitive P. falciparum 3D7 strain. In vivo evaluation employed Peter's 4-d suppressive test in P. berghei ANKA-infected Swiss albino mice administered oral doses of 20–400 mg/kg. Acute toxicity was assessed according to the OECD 423 guidelines through haematological, biochemical, oxidative stress, and histopathological analyses. In vitro, IM1 demonstrated higher intrinsic potency, exhibiting a half-maximal inhibitory concentration (IC50) of 3.6 ± 0.2 μg/mL compared to 7.8 ± 0.5 μg/mL for IM2. However, in vivo evaluation revealed a distinct efficacy paradox: IM2 demonstrated superior systemic efficacy, achieving up to 68% parasitaemia suppression at 400 mg/kg, surpassing the 52% suppression observed with IM1. IM2 also significantly extended the mean survival time of infected mice to 12.3 d, compared with 8.1 d for untreated controls. Systemically, IM2 maintained physiological homeostasis, preserved hepatic and renal architecture, and induced significant modulation and stabilization of circulating lymphocytes (p=0.049), compared with the abnormal increase observed in untreated infections. A strong positive correlation between malondialdehyde and glutathione (r=0.839, p=0.005) indicated a well-tolerated, reactive oxygen species-mediated parasiticidal mechanism for IM2. On the other hand, high-dose IM1 (400 mg/kg) induced dose-dependent hepatotoxicity, as evidenced by elevated alanine aminotransferase (44.47 U/L) and histopathological evidence of hepatocyte vacuolation. Ultimately, whilst IM1's highly lipophilic core necessitates structural optimization to mitigate hepatic stress, IM2 represents a promising lead compound that requires further pre-clinical investigations.

DSpace software copyright © 2002-2026 LYRASIS

  • Privacy policy
  • End User Agreement
  • Send Feedback
Repository logo COAR Notify